Choriogonadotropin alfa and Chorionic gonadotropin interaction
Choriogonadotropin alfa and Chorionic gonadotropin: the Choriogonadotropin alfa prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Choriogonadotropin alfa (Pregnyl) label · effective 2025-12-02
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis.
Women with known risk factors for a high ovarian response may be especially prone to the development of OHSS during or following treatment with PREGNYL.
Adherence to the recommended PREGNYL dose and treatment regimen and careful monitoring of ovarian response is important to reduce the risk of OHSS.
Advise women of the potential risk of multiple births before starting treatment with gonadotropins including PREGNYL.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PREGNYL and any potential adverse effects on the breastfed child from PREGNYL or from the underlying maternal condition.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.